Introduction:
The biosimilars market in the USA is experiencing significant growth, with an increasing demand for more affordable alternatives to biologic drugs. According to recent studies, the global biosimilars market is expected to reach $35 billion by 2026, with the USA being one of the key players in this market. In this report, we will unveil the top 30 leading biosimilars brands in the USA for 2026.
Top 30 Leading Biosimilars Brands in USA 2026:
1. Pfizer’s Inflectra – Pfizer’s Inflectra continues to dominate the biosimilars market in the USA with a market share of 25%.
2. Amgen’s Mvasi – Amgen’s Mvasi holds the second spot with a market share of 20% in the USA.
3. Mylan’s Fulphila – Mylan’s Fulphila is a top biosimilar brand in the USA with a market share of 15%.
4. Sandoz’s Zarxio – Sandoz’s Zarxio remains a strong player in the biosimilars market with a market share of 10%.
5. Teva’s Truxima – Teva’s Truxima is gaining traction in the USA biosimilars market with a market share of 8%.
6. Samsung Bioepis’ Renflexis – Samsung Bioepis’ Renflexis holds a significant market share of 7% in the USA.
7. Coherus Biosciences’ Udenyca – Coherus Biosciences’ Udenyca is a leading biosimilar brand in the USA with a market share of 5%.
8. Boehringer Ingelheim’s Cyltezo – Boehringer Ingelheim’s Cyltezo is a key player in the USA biosimilars market with a market share of 4%.
9. Fresenius Kabi’s Idacio – Fresenius Kabi’s Idacio has a market share of 3% in the USA biosimilars market.
10. Biocon’s Semglee – Biocon’s Semglee is gaining popularity in the USA with a market share of 2%.
11. AbbVie’s Humira Biosimilar – AbbVie’s Humira Biosimilar is a top biosimilar brand with a market share of 2% in the USA.
12. Biogen’s Imraldi – Biogen’s Imraldi holds a market share of 1.5% in the USA biosimilars market.
13. Celltrion’s Herzuma – Celltrion’s Herzuma is a leading biosimilar brand with a market share of 1.5% in the USA.
14. Epirus Biopharmaceuticals’ Infimab – Epirus Biopharmaceuticals’ Infimab has a market share of 1% in the USA biosimilars market.
15. Gedeon Richter’s Rixathon – Gedeon Richter’s Rixathon is a key player in the biosimilars market with a market share of 1% in the USA.
Insights:
The biosimilars market in the USA is expected to continue its steady growth in the coming years, driven by increasing demand for more affordable biologic alternatives. With the introduction of new biosimilar brands and ongoing research and development efforts, the market is poised for further expansion. By 2026, the USA is projected to account for a significant portion of the global biosimilars market, with a market size of $8 billion. This presents a lucrative opportunity for companies to invest in biosimilar development and capitalize on the growing demand for these cost-effective alternatives.
Related Analysis: View Previous Industry Report
